Detailed breakdown of funding by disease, themed area and corresponding type of science along the R&D value chain
| Disease | Preclinical | Phases I–III | Product development | Operational | ||||
|---|---|---|---|---|---|---|---|---|
| Study numbers | Funding | Study numbers | Funding | Study numbers | Funding | Study numbers | Funding | |
| Mycology | 125 | £42 244 247 | 5 | £2 008 147 | 11 | £1 536 372 | 30 | £2 615 719 |
| Pathogen | ||||||||
| Aspergillus | 20 | £4 526 214 | 1 | £6721 | 0 | £0 | 5 | £320 923 |
| Candida | 70 | £21 598 686 | 0 | £0 | 0 | £0 | 6 | £1 183 245 |
| Cryptococcosis | 5 | £1 668 260 | 1 | £1 234 684 | 3 | £578 591 | 0 | £0 |
| Paracoccidioides | 4 | £462 478 | 0 | £0 | 0 | £0 | 0 | £0 |
| Infection group* | ||||||||
| Respiratory | 26 | £5 620 674 | 3 | £1 789 554 | 3 | £578 591 | 6 | £410 477 |
| Dermatology | 2 | £342 617 | 0 | £0 | 1 | £8588 | 2 | £55 801 |
| STIs | 3 | £297 416 | 0 | £0 | 0 | £0 | 2 | £41 760 |
*For pathogens with multiple modes of entry and sites of impact, for example, Candida, studies could only be applied to infection groups if they explicitly mentioned the route of transmission or site of infection. This was often not the case particularly with preclinical studies.
STIs, sexually transmitted infections.